e-learning
resources
Virtual 2021
07.09.2021
The ongoing threat of drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
D. Butov (Kharkiv, Ukraine), M. Kuzhko (Kiev, Ukraine), M. Gumeniuk (Kiev, Ukraine), O. Denysov (Kiev, Ukraine), T. Butova (Merefa, Ukraine)
Source:
Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Session:
The ongoing threat of drug-resistant tuberculosis
Session type:
E-poster
Number:
3335
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Butov (Kharkiv, Ukraine), M. Kuzhko (Kiev, Ukraine), M. Gumeniuk (Kiev, Ukraine), O. Denysov (Kiev, Ukraine), T. Butova (Merefa, Ukraine). Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy. 3335
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 290s
Year: 2006
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Effectiveness of chemotherapy in newly detected patients with pulmonary tuberculosis with poly-resistance
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Secondary drug resistance during an intravenous intermittent chemotherapy in newly cases TB
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses
Source: Eur Respir J 2003; 22: Suppl. 45, 41s
Year: 2003
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Year: 2008
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept